Please login to the form below

Not currently logged in
Email:
Password:

Novartis reveals USD 400m of further cuts

Novartis reveals plans to make additional savings of USD 400m at its pharmaceutical business in addition to the previously announced USD 1bn of cuts

Swiss-based pharmaceutical company Novartis has revealed plans to make additional savings of USD 400m at its pharmaceutical business in addition to the previously announced USD 1bn of cuts, according to local media reports.

The SonntagsZeitung newspaper said that Novartis' head of pharmaceuticals, Thomas Ebeling, had confirmed the new plans in discussions with analysts at the group's Pharma Brand and Business Review on 12 September.

Novartis instituted the cuts to make savings in marketing and sales, where costs rose 11 per cent in 2006.

The newspaper also reported that Novartis was going to make big cuts in its US salesforce after recent product setbacks, after the company expanded it by between 6,000-7,000 in 2006.

17th September 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics